GBALLGIGGSPHOTO/ShutterstockInjection of long-acting cabotegravir and rilpivirine into the thigh muscle led to mostly mild side effects and a pharmacokinetic profile comparable to that of standard buttocks injections, according to a study presented last week at the 24th International AIDS Conference (AIDS 2022) in Montreal. Another research team found that a higher-concentration formulation of injectable cabotegravir had similar safety and produced drug levels comparable to those of the current version.
Both studies could help pave the way for self-administration of cabotegravir plus rilpivirine for HIV treatment or cabotegravir alone for PrEP (regular medication to prevent HIV infection), which could overcome one of the main barriers to wider adoption of the long-acting agents.
Read the full story at Aidsmap.
For more coverage of AIDS 2022, click here.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.